Wei Mao Ling, Kang Deying, Gu Lijia, Qiu Meng, Zhengyin Liao, Mu Yanming
Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.
Cochrane Database Syst Rev. 2013 Aug 23;2013(8):CD008588. doi: 10.1002/14651858.CD008588.pub2.
Thymic carcinoma or advanced thymoma is a rare cancer of the thymus gland that tends to be aggressive and infiltrate neighbouring organs, making total resection very difficult. Induction or adjuvant chemotherapy, or both, are often used in a multimodality approach to treat people affected by this condition, but the effectiveness of chemotherapy for thymic carcinoma or advanced thymoma remains uncertain.
To assess the role of chemotherapy in adults with thymic carcinoma or advanced thymoma.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 7), MEDLINE (accessed via Ovid from 1966 to July 2012), EMBASE (accessed via Ovid, from 1980 to July 2012), Latin American and Caribbean Literature on Health Sciences (LILACS), the Chinese Biological Medicine Database (CBM, 1978 to July 2012), China National Knowledge Infrastructure (CNKI, 1980 to July 2012) and the Chinese scientific periodical database VIP Information (VIP, 1989 to July 2012). There was no language restriction in searching for studies.
We planned to include randomised controlled trials (RCTs) of trials using chemotherapy (either single-agent or combination chemotherapy plus surgery, radiotherapy or not) for thymic carcinoma and/or advanced thymoma. We planned to include all adults (aged 18 years and over) diagnosed with thymic carcinoma and/or with Masaoka stage III or IV thymic tumours. The intended primary outcomes were overall survival (OS) and progression-free survival (PFS).
Two review authors independently evaluated the search results according to the inclusion and exclusion criteria. There were no studies identified for inclusion and therefore no data extraction was completed.
No RCTs were eligible for inclusion in this review. We report details of excluded prospective studies in an additional table and try to provide some useful evidence regarding current practice.
AUTHORS' CONCLUSIONS: There were no RCTs eligible for inclusion in this review. In current practice the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin-based chemotherapy. Considering the condition is rare, it is suggested that an international group is set up to organise and evaluate prospective collection of data from cohorts of patients to inform current clinical practice.
胸腺癌或晚期胸腺瘤是一种罕见的胸腺癌症，往往具有侵袭性，并会浸润邻近器官，这使得完全切除非常困难。诱导化疗或辅助化疗，或两者兼用，常用于多模式治疗受此疾病影响的患者，但化疗对胸腺癌或晚期胸腺瘤的有效性仍不确定。
评估化疗在成人胸腺癌或晚期胸腺瘤患者中的作用。
我们检索了Cochrane对照试验中心注册库（CENTRAL 2012年第7期）、MEDLINE（通过Ovid检索1966年至2012年7月）、EMBASE（通过Ovid检索1980年至2012年7月）、拉丁美洲和加勒比地区健康科学文献数据库（LILACS）、中国生物医学数据库（CBM，1978年至2012年7月）、中国知网（CNKI，1980年至2012年7月）和中文科技期刊数据库维普资讯（VIP，1989年至2012年7月）。检索研究时没有语言限制。
我们计划纳入使用化疗（单药或联合化疗加手术、放疗与否）治疗胸腺癌和/或晚期胸腺瘤的随机对照试验（RCT）。我们计划纳入所有诊断为胸腺癌和/或Masaoka III期或IV期胸腺肿瘤的成年人（18岁及以上）。预期的主要结局是总生存期（OS）和无进展生存期（PFS）。
两位综述作者根据纳入和排除标准独立评估检索结果。未识别出符合纳入标准的研究，因此未完成数据提取。
没有RCT符合纳入本综述的条件。我们在另一张表格中报告了排除的前瞻性研究的详细信息，并试图提供一些有关当前实践的有用证据。
没有RCT符合纳入本综述的条件。在当前实践中，成人胸腺癌或晚期胸腺瘤患者最常用的治疗方案是以顺铂为基础的化疗。考虑到这种疾病罕见，建议成立一个国际小组来组织和评估来自患者队列的前瞻性数据收集，为当前临床实践提供信息。
